remimazolam + fentanyl

Remimazolam + fentanyl is a sedation and analgesia protocol being evaluated by the Humanitas Clinical and Research Center for use during colonoscopies in adult patients with inflammatory bowel disease (IBD). Remimazolam is an ultra-short-acting benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, offering rapid onset and offset of sedation due to its metabolism by non-specific tissue esterases. Fentanyl is a potent synthetic opioid that acts as an agonist at the mu-opioid receptor, providing the necessary analgesia for invasive endoscopic procedures. This combination is specifically being compared against the standard midazolam and fentanyl regimen to assess its impact on patient satisfaction, hemodynamic stability, and recovery efficiency in the context of IBD management.